SI-BONE (SIBN) Proxy filing summary

Executive summary

• Achieved worldwide revenue of $200.9 million in 2025, a 20% increase year-over-year, with positive Adjusted EBITDA of $8.9 million and a net loss improvement of 39% to $18.9 million.

• Over 2,400 U.S. physicians performed nearly 22,000 procedures; cumulative procedures surpassed 140,000 globally since inception.

• Ended 2025 with $147.8 million in cash and equivalents; launched iFuse TORQ in Europe and secured New Technology Add-On Payment for iFuse TORQ TNT.

• The annual meeting will be held virtually on June 4, 2026, with voting available online, by phone, or by mail.

Voting matters and shareholder proposals

• Election of two directors to serve until the 2029 annual meeting.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory, non-binding vote on executive compensation (say-on-pay).

• Shareholder proposals for the 2027 meeting must be submitted by December 22, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• Board will reduce to seven members after the meeting; majority are independent per Nasdaq standards.

• Board is classified with staggered three-year terms; supermajority required to amend governance structure.

• Board committees: Audit, Compensation, and Nominating & Corporate Governance, each with defined charters and independent chairs.

• Stock ownership guidelines require CEO to hold shares worth 3x base salary; directors 3x annual retainer.

• Prohibition on hedging, pledging, and speculative transactions for directors, officers, and employees.